Scope of preclinical testing versus quality control within experiments

Stroke

Volumn 40, Issue 7, 2009, Pages

  O'Collins, Victoria E ^a   Donnan, Geoffrey A ^a,b   Macleod, Malcolm R ^c   Howells, David W ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXPERIMENTAL STUDY; HUMAN; LETTER; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

BENZENESULFONATES; CARDIOVASCULAR AGENTS; HUMANS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; STROKE; TREATMENT OUTCOME;

EID: 67650076487     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.550335     Document Type: Letter

References (6)

1. Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke. 2009;40:577-581.
2. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477.
3. STAIR. Recommendations for standards regarding preclinical neuropro-tective and restorative drug development. Stroke. 1999;30:2752-2758.
4. Donnan GA. The 2007 Feinberg lecture: a new road map for neuropro-tection. Stroke. 2008;39:242.
5. Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke. 2008;39: 2824-2829.
6. Macleod MM, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, Buchan A, van der Worp HB, Traystman R, Minematsu K, Donnan GA, Howells DW. Good laboratory practice: preventing introduction of bias at the bench. Stroke. 2009;40:e50-e52.